• Functional Protein Market Trends, Growth, Size, Segmentation, Future Demands, Latest Innovation, Regional Forecast to 2028

    The global functional protein market is expected to rise in the coming years, owing to the increasing demand for plant-based proteins and awareness about healthy dietary supplement consumption. Fortune Business Insights™ publishes this information in a report titled, "Functional Protein Market, 2021-2028". As per the report, the functional protein market size was USD 5.24 billion in 2020. The market size is expected to rise from USD 6.20 billion in 2021 to USD 15.98 billion by 2028 at a CAGR of 14.48% during the forecast period of 2021-2028.

    Functional proteins allow repairing and building body tissues and coordinate bodily functions by encouraging metabolic reactions to take place efficiently. These proteins provide a structural framework to the body and maintain proper pH and fluid balance. Rising demand for plant-based proteins and dietary supplements to adopt a healthy lifestyle is likely to fuel the market growth during the forecast period.


    List of Key Players Profiled in Market Report for Functional Protein:

    DuPont Nutrition (U.S.)
    Essentia Protein Solutions (U.S.)
    Glanbia plc (Ireland)
    ProtiFarm (Netherlands)
    ADM (U.S.)
    AMCO Proteins (U.S.)
    DSM (Netherlands)
    Merit Functional Foods (Canada)
    Plantible Foods (U.S.)
    Roquette Frères (France)
    Browse A Complate Research Report:

    https://www.fortunebusinessinsights.com/functional-proteins-market-102458

    Segments:

    Rising Protein Utilization in Meat & Poultry Application to Stimulate Growth

    By source, the market is bifurcated into animal and plant-based proteins.

    Based on the application, the market trifurcated into functional food & beverages, animal feed, and dietary supplements.

    Finally, by geography, the market is categorized into North America, Europe, Asia Pacific, South America, and the Middle East & Africa.

    Report Coverage:

    The report provides complete information and factual data regarding market development and recent trends in product development strategies. Also, the report sheds light on the impact of the COVID-19 pandemic on market growth and industrial expansion globally. Furthermore, drivers and restraints affecting market development in segmented regions are highlighted in the report. Key market players and their business development strategy are discussed further, along with key industrial development in recent years.

    Drivers & Restraints:

    Rising Demand for Plant-Based Protein to Fuel Market

    The market is expected to witness a high growth rate in the coming years due to the increasing consumption of dietary supplements and rising demand for plant-based proteins. These proteins are considered prominent alternatives to meat products to provide adequate protein. Consumers are willing to invest in health supplements and improve their immune systems to fight against viruses. Increasing demands for these proteins in competitive sports, body toning, and muscle-building activities are expected to drive the market during the projected period. These factors will likely ensure functional protein market growth in the coming years.

    However, animal welfare sentiments may hinder the protein production sourced from the animal segment.

    Regional Insights:

    Asia Pacific Dominates Market Due to Rising Population

    Asia Pacific dominates the global functional protein market share, where the region held its position by holding USD 1.82 billion in 2020. Increasing population and economic growth are attributed to exhibit exponential market growth in the coming years. Furthermore, rising income levels and increasing spending capacity of the population are anticipated to drive the market during the forecast period.

    North America is expected to hold the second-largest global market share due to the rising dietary supplements consumption among the population. Increasing demand for these proteins on a daily basis is likely to boost the market and propel growth.

    Competitive Landscape:

    Innovative Product Development Allow Key Players to Sustain Market Position

    Key players in the market focus on implementing innovative product development and differentiation strategies to propel growth and gain a competitive advantage. Also, the major companies focus on implementing growth strategies such as partnerships, alliances, acquisitions, and mergers.

    Industry Developments:

    July 2021: ADM acquired Soja protein, a popular European producer of non-GMO soy ingredients. This acquisition underlines the expansion of ADM's global alternative protein portfolio.
    May 2020: Unilever entered into a partnership with food-tech firm ENOUGH to launch new plant-based meat products to market. The new product ABUNDA mycoprotein is a food ingredient containing essential amino acids and is high in dietary fiber.
    Functional Protein Market Trends, Growth, Size, Segmentation, Future Demands, Latest Innovation, Regional Forecast to 2028 The global functional protein market is expected to rise in the coming years, owing to the increasing demand for plant-based proteins and awareness about healthy dietary supplement consumption. Fortune Business Insights™ publishes this information in a report titled, "Functional Protein Market, 2021-2028". As per the report, the functional protein market size was USD 5.24 billion in 2020. The market size is expected to rise from USD 6.20 billion in 2021 to USD 15.98 billion by 2028 at a CAGR of 14.48% during the forecast period of 2021-2028. Functional proteins allow repairing and building body tissues and coordinate bodily functions by encouraging metabolic reactions to take place efficiently. These proteins provide a structural framework to the body and maintain proper pH and fluid balance. Rising demand for plant-based proteins and dietary supplements to adopt a healthy lifestyle is likely to fuel the market growth during the forecast period. List of Key Players Profiled in Market Report for Functional Protein: DuPont Nutrition (U.S.) Essentia Protein Solutions (U.S.) Glanbia plc (Ireland) ProtiFarm (Netherlands) ADM (U.S.) AMCO Proteins (U.S.) DSM (Netherlands) Merit Functional Foods (Canada) Plantible Foods (U.S.) Roquette Frères (France) Browse A Complate Research Report: https://www.fortunebusinessinsights.com/functional-proteins-market-102458 Segments: Rising Protein Utilization in Meat & Poultry Application to Stimulate Growth By source, the market is bifurcated into animal and plant-based proteins. Based on the application, the market trifurcated into functional food & beverages, animal feed, and dietary supplements. Finally, by geography, the market is categorized into North America, Europe, Asia Pacific, South America, and the Middle East & Africa. Report Coverage: The report provides complete information and factual data regarding market development and recent trends in product development strategies. Also, the report sheds light on the impact of the COVID-19 pandemic on market growth and industrial expansion globally. Furthermore, drivers and restraints affecting market development in segmented regions are highlighted in the report. Key market players and their business development strategy are discussed further, along with key industrial development in recent years. Drivers & Restraints: Rising Demand for Plant-Based Protein to Fuel Market The market is expected to witness a high growth rate in the coming years due to the increasing consumption of dietary supplements and rising demand for plant-based proteins. These proteins are considered prominent alternatives to meat products to provide adequate protein. Consumers are willing to invest in health supplements and improve their immune systems to fight against viruses. Increasing demands for these proteins in competitive sports, body toning, and muscle-building activities are expected to drive the market during the projected period. These factors will likely ensure functional protein market growth in the coming years. However, animal welfare sentiments may hinder the protein production sourced from the animal segment. Regional Insights: Asia Pacific Dominates Market Due to Rising Population Asia Pacific dominates the global functional protein market share, where the region held its position by holding USD 1.82 billion in 2020. Increasing population and economic growth are attributed to exhibit exponential market growth in the coming years. Furthermore, rising income levels and increasing spending capacity of the population are anticipated to drive the market during the forecast period. North America is expected to hold the second-largest global market share due to the rising dietary supplements consumption among the population. Increasing demand for these proteins on a daily basis is likely to boost the market and propel growth. Competitive Landscape: Innovative Product Development Allow Key Players to Sustain Market Position Key players in the market focus on implementing innovative product development and differentiation strategies to propel growth and gain a competitive advantage. Also, the major companies focus on implementing growth strategies such as partnerships, alliances, acquisitions, and mergers. Industry Developments: July 2021: ADM acquired Soja protein, a popular European producer of non-GMO soy ingredients. This acquisition underlines the expansion of ADM's global alternative protein portfolio. May 2020: Unilever entered into a partnership with food-tech firm ENOUGH to launch new plant-based meat products to market. The new product ABUNDA mycoprotein is a food ingredient containing essential amino acids and is high in dietary fiber.
    Functional Protein Market Size, Share, Trends | Forecast [2028]
    The global functional protein market is projected to grow from $6.20 billion in 2021 to $15.98 billion in 2028 at a CAGR of 14.48% in forecast period, 2021-2028
    WWW.FORTUNEBUSINESSINSIGHTS.COM
    0 Comments 0 Shares
  • The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030

    Recent advances in molecular biology have enabled researchers to develop a better understanding of the rare soft tissue sarcomas; as a result, a number of viable biological targets have been identified and are being investigated for therapeutic relevance

    Roots Analysis has announced the addition of “Soft Tissue Sarcoma: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report to its list of offerings.

    Soft tissue sarcoma is a rare form of cancer that usually originates in soft / connective tissues and most commonly affects the abdomen, arms, head, legs, neck and trunk of the individual. It is worth noting that, till date, many types (50+) of soft tissue sarcoma have been identified. However, since these tumors possess a large set of entities, their diagnosis is often difficult. At present, there is a growing need for effective and targeted treatment options.

    To order this 130+ slides report, which features 80+ figures, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html.

    Key Market Insights

    70+ therapeutics have been / are being developed for the treatment of angiosarcoma, chondrosarcoma and liposarcoma
    Nearly 95% of the aforementioned therapeutic candidates are under clinical evaluation. Further, two therapies, namely YONDELIS® and HALAVEN®, have been approved for the treatment of liposarcoma.

    Around 65% of the therapeutics are being developed as small molecules
    Majority (over 65%) of the abovementioned drugs have been / are being developed for administration via the oral route. Notably, about 60% of the soft tissue sarcoma targeting therapeutics have been / are being developed for use as the 1st line of treatment.

    More than 50 industry and non-industry players are engaged in the soft tissue sarcoma market
    North America has emerged as a key hub, featuring the presence of close to 60% developers. The developer landscape is further dominated by players that have been established after 1990, representing around 45% of the total number of stakeholders.

    Around 190 trials, evaluating therapies for soft tissue sarcoma, have been registered
    More than 22,000 patients have been enrolled in clinical research initiatives aimed to validate the efficacy and safety of soft tissue sarcoma targeting therapeutics. Interestingly, 60% of the overall trials are phase II studies; of these, 50% are currently active.

    Partnership activity in this field has increased at a CAGR of 70%, between 2018 and 2020
    About 80% of the reported deals were established in the last three years, with the maximum activity being reported in 2020. Majority of the instances captured in the report were licensing agreements (45%). Further, more than 50% of the agreements were observed to be signed for therapeutics targeting liposarcoma.

    More than 260 articles have been published related to soft tissue sarcoma, since January 2021
    Around 40% publications mentioned in the report were focused on the assessment of therapeutics that have been / are being developed for the treatment of angiosarcoma. Example of prominent journals include (in decreasing order of number of publications) BMJ Case Rep, Skeletal Radiol, Ann Surg Oncol and Cureus.

    Around 75 eminent scientists were identified as key opinion leaders (KOLs)
    65% of these KOLs were observed to be associated with organizations based in North America, followed by those affiliated to institutes in Europe (30%) and Asia-Pacific (5%). Further, majority (50%) of the KOLs are currently affiliated to academic institutes, such as schools and universities.

    North America is anticipated to capture over 70% of the global market share in 2030
    In 2030, nearly 80% of the market revenues are expected to be generated from sales of therapeutics that intended for the treatment of liposarcoma. Further, therapies designed for intravenous administration are expected to occupy a larger share (60%) of the overall market in 2030.

    To request a sample copy / brochure of this report, please visit this
    https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market/request-sample.html

    Key Questions Answered
     Who are the leading players engaged in the development of soft tissue sarcoma targeting therapeutics?
     Which is the most popular type of soft tissue sarcoma, based on the ongoing activity in the market?
     Which are the most common routes of administration for soft tissue sarcoma targeting therapeutics?
     Which companies are actively involved in conducting clinical trials for their therapeutic candidates?
     Which partnership models are most commonly adopted by stakeholders in this industry?
     What is the evolving trend related to the focus of publications related to soft tissue sarcoma targeting therapeutics?
     Who are the prominent KOLs evaluating therapies within this industry?
     What opportunities are available for soft tissue sarcoma targeting therapeutics in emerging markets?
     How is the current and future opportunity likely to be distributed across key market segments?


    The USD 421 million (by 2030) financial opportunity within the soft tissue sarcoma targeting therapeutics market has been analyzed across the following segments:

     Drug Class
     Biologics
     Small Molecules

     Route of Administration
     Intravenous Drugs
     Oral Drugs

     Type of Soft Tissue Sarcoma
     Angiosarcoma
     Chondrosarcoma
     Liposarcoma

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific
     Rest of the World

    The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.

     Adaptimmune
     Agios Pharmaceuticals
     Agenus
     Athenex
     Eisai
     Eli Lilly
     GlaxoSmithKline
     Karyopharm Therapeutics
     Mirati Therapeutics
     PharmaMar

    For additional details, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030 Recent advances in molecular biology have enabled researchers to develop a better understanding of the rare soft tissue sarcomas; as a result, a number of viable biological targets have been identified and are being investigated for therapeutic relevance Roots Analysis has announced the addition of “Soft Tissue Sarcoma: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report to its list of offerings. Soft tissue sarcoma is a rare form of cancer that usually originates in soft / connective tissues and most commonly affects the abdomen, arms, head, legs, neck and trunk of the individual. It is worth noting that, till date, many types (50+) of soft tissue sarcoma have been identified. However, since these tumors possess a large set of entities, their diagnosis is often difficult. At present, there is a growing need for effective and targeted treatment options. To order this 130+ slides report, which features 80+ figures, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html. Key Market Insights 70+ therapeutics have been / are being developed for the treatment of angiosarcoma, chondrosarcoma and liposarcoma Nearly 95% of the aforementioned therapeutic candidates are under clinical evaluation. Further, two therapies, namely YONDELIS® and HALAVEN®, have been approved for the treatment of liposarcoma. Around 65% of the therapeutics are being developed as small molecules Majority (over 65%) of the abovementioned drugs have been / are being developed for administration via the oral route. Notably, about 60% of the soft tissue sarcoma targeting therapeutics have been / are being developed for use as the 1st line of treatment. More than 50 industry and non-industry players are engaged in the soft tissue sarcoma market North America has emerged as a key hub, featuring the presence of close to 60% developers. The developer landscape is further dominated by players that have been established after 1990, representing around 45% of the total number of stakeholders. Around 190 trials, evaluating therapies for soft tissue sarcoma, have been registered More than 22,000 patients have been enrolled in clinical research initiatives aimed to validate the efficacy and safety of soft tissue sarcoma targeting therapeutics. Interestingly, 60% of the overall trials are phase II studies; of these, 50% are currently active. Partnership activity in this field has increased at a CAGR of 70%, between 2018 and 2020 About 80% of the reported deals were established in the last three years, with the maximum activity being reported in 2020. Majority of the instances captured in the report were licensing agreements (45%). Further, more than 50% of the agreements were observed to be signed for therapeutics targeting liposarcoma. More than 260 articles have been published related to soft tissue sarcoma, since January 2021 Around 40% publications mentioned in the report were focused on the assessment of therapeutics that have been / are being developed for the treatment of angiosarcoma. Example of prominent journals include (in decreasing order of number of publications) BMJ Case Rep, Skeletal Radiol, Ann Surg Oncol and Cureus. Around 75 eminent scientists were identified as key opinion leaders (KOLs) 65% of these KOLs were observed to be associated with organizations based in North America, followed by those affiliated to institutes in Europe (30%) and Asia-Pacific (5%). Further, majority (50%) of the KOLs are currently affiliated to academic institutes, such as schools and universities. North America is anticipated to capture over 70% of the global market share in 2030 In 2030, nearly 80% of the market revenues are expected to be generated from sales of therapeutics that intended for the treatment of liposarcoma. Further, therapies designed for intravenous administration are expected to occupy a larger share (60%) of the overall market in 2030. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market/request-sample.html Key Questions Answered  Who are the leading players engaged in the development of soft tissue sarcoma targeting therapeutics?  Which is the most popular type of soft tissue sarcoma, based on the ongoing activity in the market?  Which are the most common routes of administration for soft tissue sarcoma targeting therapeutics?  Which companies are actively involved in conducting clinical trials for their therapeutic candidates?  Which partnership models are most commonly adopted by stakeholders in this industry?  What is the evolving trend related to the focus of publications related to soft tissue sarcoma targeting therapeutics?  Who are the prominent KOLs evaluating therapies within this industry?  What opportunities are available for soft tissue sarcoma targeting therapeutics in emerging markets?  How is the current and future opportunity likely to be distributed across key market segments? The USD 421 million (by 2030) financial opportunity within the soft tissue sarcoma targeting therapeutics market has been analyzed across the following segments:  Drug Class  Biologics  Small Molecules  Route of Administration  Intravenous Drugs  Oral Drugs  Type of Soft Tissue Sarcoma  Angiosarcoma  Chondrosarcoma  Liposarcoma  Key Geographical Regions  North America  Europe  Asia-Pacific  Rest of the World The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.  Adaptimmune  Agios Pharmaceuticals  Agenus  Athenex  Eisai  Eli Lilly  GlaxoSmithKline  Karyopharm Therapeutics  Mirati Therapeutics  PharmaMar For additional details, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    0 Comments 0 Shares
  • The CAR-T therapies market is characterized by a healthy pipeline of promising therapies

    Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market

    Roots Analysis has announced the addition of “CAR-T Cell Therapy Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings.

    Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status. With four approved products and many candidate therapies under evaluation for the treatment of multiple disease indications, the CAR-T cell therapy market is characterized by a healthy and growing pipeline. Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity.

    To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html

    Key Market Insights

    Over 755 CAR-T cell therapies are currently approved / under development
    Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 25% are being evaluated in clinical stages (phase I/II and above). Examples of late-stage clinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T / JNJ-68284528.

    Currently, the focus is on developing product candidates to treat various types of cancers
    Over 95% of the products in the development pipeline are being evaluated for the treatment of hematological malignancies, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia. Only 2% of current pipeline candidates are being developed for the treatment of non-oncological indications.

    Extensive efforts are underway to improve CAR constructs
    Majority of the product candidates in the clinical pipeline, including the four approved drug products, are based on second generation CARs. Further, a number of novel therapies armed with fourth generation CAR constructs, CAR-based products containing humanized scFv and bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluated worldwide.

    China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals
    In the last 10 years, over half of the 410 clinical trials evaluating various types of CAR-T cell therapies, were registered in China. In addition, owning to a favorable clinical research environment, China is presently considered to be among the leading regions in the CAR-T cell therapy space, with close to 40 industry players and more than 100 non-industry players, including hospitals and universities, contributing to this field.

    Partnership activity within this domain has grown at a CAGR of 26%, between 2011 and 2020
    More than 220 agreements were inked related to CAR-T cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (21%), technology licensing (20%) and product development and commercialization agreements (11%).

    Over USD 13 billion has been invested by both private and public investors, across more than 205 instances
    It is important to mention that, between 2013 and 2020, majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), grants (12%) and secondary offerings (12%).

    The market is anticipated to grow at a CAGR of over 28%, during the period 2021-2030
    Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the recent success of the four approved CAR-T cell therapies. North America (primarily the US) and Europe are expected to capture over 75% of the market share by 2030, in terms of the sales-based revenues.

    To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html

    Key Questions Answered
     Who are the leading industry and non-industry players in this market?
     What are the prevalent R&D trends in CAR-T cell therapies domain?
     What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?
     What are the challenges faced by stakeholders in this industry?
     Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?
     Who are the key investors in this domain?
     Who are the key opinion leaders / experts that can help in driving product development efforts in this field?
     What kind of partnership models are commonly adopted by industry stakeholders?
     What kind of contract manufacturing support is available for CAR-T cell therapies?
     What kind of promotional strategies are likely to be adopted for CAR-T cell therapies that are approved / commercialized in future?
     What are the factors that are likely to influence the evolution of this upcoming market?
     How is the current and future market opportunity likely to be distributed across key market segments?


    The USD 14 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments:

     Disease indication
     Non-Hodgkin lymphoma
     Multiple myeloma
     Chronic lymphocytic leukemia
     Acute lymphoblastic leukemia
     Follicular lymphoma
     Mantle cell lymphoma
     Hepatocellular carcinoma
     Colorectal cancer

     Target antigens
     CD19
     BCMA
     CD19, CD22
     GPC3
     EGFR

     Key Geographical Regions
     North America
     Europe
     Asia Pacific
     Latin America
     Middle East and North Africa
     Rest of the World

    The report features inputs from eminent industry stakeholders, according to whom CAR-T cell therapies are soon likely to witness increased adoption given their broad scope of applications in various advanced stage oncological disorders. The report includes detailed transcripts of discussions held with the following experts:
     Tim Oldham (Chief Executive Officer, Cell Therapies)
     Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
     Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)
     Miguel Forte (Chief Operating Officer, TxCell)
     Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
     Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
     Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
     Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
     Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
     Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

    The research includes brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies.
     Autolus
     bluebird bio
     CARsgen Therapeutics
     Celgene (A Bristol Myers Squibb Company)
     Cellectis
     Cellular Biomedicine Group
     Innovative Cellular Therapeutics
     Iovance Biotherapeutics
     Kite Pharma (A Gilead Sciences Company)
     Kuur Therapeutics
     Noile-Immune Biotech
     Novartis
     Shanghai Genechem
     Sinobioway Cell Therapy
     Takara Bio
     Ziopharm Oncology

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Global T-Cell Therapies Market (5th Edition), 2021 – 2030
    2. mRNA Therapeutics and Vaccines Market, 2020-2030
    3. Gene Therapies Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030
    4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The CAR-T therapies market is characterized by a healthy pipeline of promising therapies Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market Roots Analysis has announced the addition of “CAR-T Cell Therapy Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings. Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status. With four approved products and many candidate therapies under evaluation for the treatment of multiple disease indications, the CAR-T cell therapy market is characterized by a healthy and growing pipeline. Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity. To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html Key Market Insights Over 755 CAR-T cell therapies are currently approved / under development Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 25% are being evaluated in clinical stages (phase I/II and above). Examples of late-stage clinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T / JNJ-68284528. Currently, the focus is on developing product candidates to treat various types of cancers Over 95% of the products in the development pipeline are being evaluated for the treatment of hematological malignancies, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia. Only 2% of current pipeline candidates are being developed for the treatment of non-oncological indications. Extensive efforts are underway to improve CAR constructs Majority of the product candidates in the clinical pipeline, including the four approved drug products, are based on second generation CARs. Further, a number of novel therapies armed with fourth generation CAR constructs, CAR-based products containing humanized scFv and bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluated worldwide. China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals In the last 10 years, over half of the 410 clinical trials evaluating various types of CAR-T cell therapies, were registered in China. In addition, owning to a favorable clinical research environment, China is presently considered to be among the leading regions in the CAR-T cell therapy space, with close to 40 industry players and more than 100 non-industry players, including hospitals and universities, contributing to this field. Partnership activity within this domain has grown at a CAGR of 26%, between 2011 and 2020 More than 220 agreements were inked related to CAR-T cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (21%), technology licensing (20%) and product development and commercialization agreements (11%). Over USD 13 billion has been invested by both private and public investors, across more than 205 instances It is important to mention that, between 2013 and 2020, majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), grants (12%) and secondary offerings (12%). The market is anticipated to grow at a CAGR of over 28%, during the period 2021-2030 Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the recent success of the four approved CAR-T cell therapies. North America (primarily the US) and Europe are expected to capture over 75% of the market share by 2030, in terms of the sales-based revenues. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html Key Questions Answered  Who are the leading industry and non-industry players in this market?  What are the prevalent R&D trends in CAR-T cell therapies domain?  What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?  What are the challenges faced by stakeholders in this industry?  Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?  Who are the key investors in this domain?  Who are the key opinion leaders / experts that can help in driving product development efforts in this field?  What kind of partnership models are commonly adopted by industry stakeholders?  What kind of contract manufacturing support is available for CAR-T cell therapies?  What kind of promotional strategies are likely to be adopted for CAR-T cell therapies that are approved / commercialized in future?  What are the factors that are likely to influence the evolution of this upcoming market?  How is the current and future market opportunity likely to be distributed across key market segments? The USD 14 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments:  Disease indication  Non-Hodgkin lymphoma  Multiple myeloma  Chronic lymphocytic leukemia  Acute lymphoblastic leukemia  Follicular lymphoma  Mantle cell lymphoma  Hepatocellular carcinoma  Colorectal cancer  Target antigens  CD19  BCMA  CD19, CD22  GPC3  EGFR  Key Geographical Regions  North America  Europe  Asia Pacific  Latin America  Middle East and North Africa  Rest of the World The report features inputs from eminent industry stakeholders, according to whom CAR-T cell therapies are soon likely to witness increased adoption given their broad scope of applications in various advanced stage oncological disorders. The report includes detailed transcripts of discussions held with the following experts:  Tim Oldham (Chief Executive Officer, Cell Therapies)  Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)  Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)  Miguel Forte (Chief Operating Officer, TxCell)  Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)  Vincent Brichard (Vice President, Immuno-Oncology, Celyad)  Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)  Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)  Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)  Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado) The research includes brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies.  Autolus  bluebird bio  CARsgen Therapeutics  Celgene (A Bristol Myers Squibb Company)  Cellectis  Cellular Biomedicine Group  Innovative Cellular Therapeutics  Iovance Biotherapeutics  Kite Pharma (A Gilead Sciences Company)  Kuur Therapeutics  Noile-Immune Biotech  Novartis  Shanghai Genechem  Sinobioway Cell Therapy  Takara Bio  Ziopharm Oncology For additional details, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Global T-Cell Therapies Market (5th Edition), 2021 – 2030 2. mRNA Therapeutics and Vaccines Market, 2020-2030 3. Gene Therapies Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030 4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    CAR-T Therapies Market (3rd Edition) | Industry Analysis | Market Size | 2030
    CAR-T Therapies market report features an extensive study of the current market landscape and future potential of the industry players
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The RNA targeting small molecule therapies market is projected to be worth around USD 8.3 billion in 2030

    In the recent years, RNA’s potential as a target molecule for small molecules has been widely recognized; as a result, a number of industry players have developed their proprietary technologies for direct and indirect RNA targeting and are actively engaged in the discovery and development of therapies against a wide range of therapeutic disorder

    Roots Analysis has announced the addition of “RNA Therapeutics Market” report to its list of offerings.

    RNAs represent a one-of-a-kind class of molecules that can interact with three different types of biological macromolecules, namely DNA, RNA and proteins which further enables the development of therapies capable of targeting previously deemed undruggable transcripts and genes. In the past few years, a number of novel techniques have been developed to expand the druggability of RNA molecules. As a result, numerous small molecules, capable of acting on current and novel RNA targets are also being investigated in clinical and preclinical studies for the treatment of various indications, such as genetic diseases, infectious diseases and different types of cancers.

    To order this 260+ page report, which features 110+ figures, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html

    Key Market Insights

    100+ RNA targeting small molecules therapeutics have been / are being developed for the treatment of different types of disease indications
    Close to 70% of the aforementioned therapeutic candidates are under preclinical evaluation. Further, two therapies, namely Translarna™ and Risdiplam, have been approved for the treatment of Duchenne Muscular Dystrophy and spinal muscular atrophy respectively.

    More than 45% of the therapies under clinical evaluation are currently in phase II developmental stage
    Around 50% of therapies under clinical evaluation are being developed to target oncological disorders; of which 53% of candidates are being evaluated under phase I clinical stage of development

    Close to 60% of the therapies under preclinical evaluation are currently in discovery phase of development
    Around 44% of the therapies under preclinical evaluation are being developed to target neurological disorders; of which close to 50% of drug candidates underwent RNA splicing modification.

    More than 55% of the players evaluating RNA Targeting small molecule therapies are small companies
    North America has emerged as a key hub, featuring the presence of 63% developers. The developer landscape is further dominated by players that have been established post-2012, representing around 68% of the total number of stakeholders

    Partnership activity in this field has increased at a CAGR of 9.1%, between 2018 and 2020
    More than 70% of the reported deals were R&D agreements, majority of which were focused on drug candidates targeting neurological disorders. Further, majority of the instances captured in the report were inked with players based in North America (65%).

    Close to USD 500 million was raised by companies involved in the development of drug candidates targeting oncological disorders
    Majority of the companies (52%) engaged in this domain primarily received funding through venture capital rounds. Further, around 90% of the funding instances were reported by players headquartered in the US.

    North America is anticipated to capture over ~70% of the global market share in 2030
    In 2030, close to 40% of the market revenues are expected to be generated from sales of therapeutics that are intended to target oncological disorders. Further, therapies designed for oral route of administration are expected to occupy a larger share (77%) of the overall market in 2030.

    To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market/request-sample.html

    Key Questions Answered
     Who are the key players engaged in the development of RNA targeting small molecule therapeutics?
     What are the current investment trends in this field?
     Which are the key therapeutic areas for which RNA targeting small molecule therapies are being developed?
     What are the different technological approaches adopted by various players for the development of RNA targeting small molecule therapeutics?
     What type of partnership models are most commonly adopted by stakeholders engaged in this domain?
     What is the relative competitiveness of different RNA targeting small molecules therapeutics developers engaged in this market?
     How is the current and future market opportunity likely to be distributed across key market segments?

    The USD XX million (by 2030) financial opportunity within the RNA targeting small molecules therapeutics market has been analyzed across the following segments:

     Drug
     Translarna™
     Risdiplam
     Tomivosertib
     ELX-02
     H3B-6545
     ABX464

     Type of Indication
     Aniridia
     Breast Cancer
     Castrate-resistant Prostate Cancer
     Colorectal Cancer
     Crohn Disease
     Cystic Fibrosis
     Duchenne Muscular Dystrophy
     Dravet Syndrome
     HIV Infections
     Impaired Renal Function
     NSCLC
     Rheumatoid Arthritis
     Spinal Muscular Atrophy
     Ulcerative Colitis

     Type of Therapeutic Area
     Autoimmune Disorders
     Genetic Disorders
     Inflammatory Disorders
     Infectious Disorders
     Kidney Disorders
     Neurological Disorders
     Oncological Disorders
     Ophthalmic Disorders
     Rare Disorders
     Respiratory Disorders

     Type of Target Molecule
     CDKL5
     Cap Binding Complex
     Dystrophin Protein
     Estrogen Receptor Alpha
     G542X
     MNK1 / MNK2 PAX6 Gene
     PAX6 Gene
     SMN2

     Type of Route of Administration
     Oral
     Subcutaneous

     Key Geographical Regions
     North America
     Europe

    The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.

     Abivax
     AC immune
     Arrakis Therapeutics
     eFFECTOR Therapeutics
     Eloxx Pharmaceuticals
     H3 Biomedicine
     PTC Therapeutics
     Ribometrix
     Skyhawk Therapeutics
     STORM Therapeutics


    For additional details, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. RAS Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    2. DNA Damage Response Targeting Therapeutics: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    3. HER2 Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The RNA targeting small molecule therapies market is projected to be worth around USD 8.3 billion in 2030 In the recent years, RNA’s potential as a target molecule for small molecules has been widely recognized; as a result, a number of industry players have developed their proprietary technologies for direct and indirect RNA targeting and are actively engaged in the discovery and development of therapies against a wide range of therapeutic disorder Roots Analysis has announced the addition of “RNA Therapeutics Market” report to its list of offerings. RNAs represent a one-of-a-kind class of molecules that can interact with three different types of biological macromolecules, namely DNA, RNA and proteins which further enables the development of therapies capable of targeting previously deemed undruggable transcripts and genes. In the past few years, a number of novel techniques have been developed to expand the druggability of RNA molecules. As a result, numerous small molecules, capable of acting on current and novel RNA targets are also being investigated in clinical and preclinical studies for the treatment of various indications, such as genetic diseases, infectious diseases and different types of cancers. To order this 260+ page report, which features 110+ figures, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html Key Market Insights 100+ RNA targeting small molecules therapeutics have been / are being developed for the treatment of different types of disease indications Close to 70% of the aforementioned therapeutic candidates are under preclinical evaluation. Further, two therapies, namely Translarna™ and Risdiplam, have been approved for the treatment of Duchenne Muscular Dystrophy and spinal muscular atrophy respectively. More than 45% of the therapies under clinical evaluation are currently in phase II developmental stage Around 50% of therapies under clinical evaluation are being developed to target oncological disorders; of which 53% of candidates are being evaluated under phase I clinical stage of development Close to 60% of the therapies under preclinical evaluation are currently in discovery phase of development Around 44% of the therapies under preclinical evaluation are being developed to target neurological disorders; of which close to 50% of drug candidates underwent RNA splicing modification. More than 55% of the players evaluating RNA Targeting small molecule therapies are small companies North America has emerged as a key hub, featuring the presence of 63% developers. The developer landscape is further dominated by players that have been established post-2012, representing around 68% of the total number of stakeholders Partnership activity in this field has increased at a CAGR of 9.1%, between 2018 and 2020 More than 70% of the reported deals were R&D agreements, majority of which were focused on drug candidates targeting neurological disorders. Further, majority of the instances captured in the report were inked with players based in North America (65%). Close to USD 500 million was raised by companies involved in the development of drug candidates targeting oncological disorders Majority of the companies (52%) engaged in this domain primarily received funding through venture capital rounds. Further, around 90% of the funding instances were reported by players headquartered in the US. North America is anticipated to capture over ~70% of the global market share in 2030 In 2030, close to 40% of the market revenues are expected to be generated from sales of therapeutics that are intended to target oncological disorders. Further, therapies designed for oral route of administration are expected to occupy a larger share (77%) of the overall market in 2030. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market/request-sample.html Key Questions Answered  Who are the key players engaged in the development of RNA targeting small molecule therapeutics?  What are the current investment trends in this field?  Which are the key therapeutic areas for which RNA targeting small molecule therapies are being developed?  What are the different technological approaches adopted by various players for the development of RNA targeting small molecule therapeutics?  What type of partnership models are most commonly adopted by stakeholders engaged in this domain?  What is the relative competitiveness of different RNA targeting small molecules therapeutics developers engaged in this market?  How is the current and future market opportunity likely to be distributed across key market segments? The USD XX million (by 2030) financial opportunity within the RNA targeting small molecules therapeutics market has been analyzed across the following segments:  Drug  Translarna™  Risdiplam  Tomivosertib  ELX-02  H3B-6545  ABX464  Type of Indication  Aniridia  Breast Cancer  Castrate-resistant Prostate Cancer  Colorectal Cancer  Crohn Disease  Cystic Fibrosis  Duchenne Muscular Dystrophy  Dravet Syndrome  HIV Infections  Impaired Renal Function  NSCLC  Rheumatoid Arthritis  Spinal Muscular Atrophy  Ulcerative Colitis  Type of Therapeutic Area  Autoimmune Disorders  Genetic Disorders  Inflammatory Disorders  Infectious Disorders  Kidney Disorders  Neurological Disorders  Oncological Disorders  Ophthalmic Disorders  Rare Disorders  Respiratory Disorders  Type of Target Molecule  CDKL5  Cap Binding Complex  Dystrophin Protein  Estrogen Receptor Alpha  G542X  MNK1 / MNK2 PAX6 Gene  PAX6 Gene  SMN2  Type of Route of Administration  Oral  Subcutaneous  Key Geographical Regions  North America  Europe The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.  Abivax  AC immune  Arrakis Therapeutics  eFFECTOR Therapeutics  Eloxx Pharmaceuticals  H3 Biomedicine  PTC Therapeutics  Ribometrix  Skyhawk Therapeutics  STORM Therapeutics For additional details, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. RAS Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 2. DNA Damage Response Targeting Therapeutics: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 3. HER2 Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    RNA Targeting Small Molecules Therapeutics Market | Market Size | Industry Analysis | 2030
    RNA Targeting Small Molecules Therapeutics / RNA translation modulators market report features an extensive study of the current market landscape and future potential of the...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • Libyan Desert Glass Jewelry | Gemstone Jewelry
    Libyan desert glass is also known as the Great Sand Sea glass, which is found in the Sahara desert of western Egypt and Eastern Libya. It is belonged to the tektite family and is formed from a meteoroid impact that happened 26 million years ago. It is associated with the solar plexus and third eye chakra. They are a highly protective gem and are beneficial to enhance your willpower, boost the immune system, and promote serenity and soothing energy to their user. Generally, Libyan desert glass jewelry is recommended for those born under the zodiac sign of Libra. The crystal sets into sterling silver metal that makes unique pair of Libyan desert glass and silver. Check out your favorite collection at Rananjay Exports.
    visit@https://www.rananjayexports.com/gemstones/libyan-desert-glass-jewelry
    Libyan Desert Glass Jewelry | Gemstone Jewelry Libyan desert glass is also known as the Great Sand Sea glass, which is found in the Sahara desert of western Egypt and Eastern Libya. It is belonged to the tektite family and is formed from a meteoroid impact that happened 26 million years ago. It is associated with the solar plexus and third eye chakra. They are a highly protective gem and are beneficial to enhance your willpower, boost the immune system, and promote serenity and soothing energy to their user. Generally, Libyan desert glass jewelry is recommended for those born under the zodiac sign of Libra. The crystal sets into sterling silver metal that makes unique pair of Libyan desert glass and silver. Check out your favorite collection at Rananjay Exports. visit@https://www.rananjayexports.com/gemstones/libyan-desert-glass-jewelry
    1 0 Comments 0 Shares
  • The CD-47 targeting therapeutics market is projected to grow at a CAGR of 42.9%, claims Roots Analysis

    Upon realizing the potential of this novel target, industry stakeholders have initiated several R&D efforts focused on exploiting the use of CD47 as an effective biomarker for the diagnosis and treatment purposes.

    Roots Analysis has announced the addition of “CD-47 Targeting Therapeutics Market, 2021-2035” report to its list of offerings.

    In recent years, the focus of the research community has shifted towards the development of novel treatment modalities, such as T- cell immunotherapies, that exhibit high efficacy. CD-47, owing to its increased expression on the surface of cancer cells, has emerged as a cancer immune checkpoint biomarker.

    To order this 190+ page report, which features 142+ figures, please visit https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html

    Key Market Insights

    Over 75 CD-47 drug candidates are under various phases of development
    52% of the pipeline candidates are currently in preclinical and discovery stages, while more than 48% therapies are being evaluated in clinical stages with most candidates being in early clinical stages (41.6%); 3.9% and 2.6% of clinical candidates being evaluated in phase II and phase III respectively.

    ~50 companies claim to be engaged in the development of CD-47 therapeutics, globally
    Since 2015, 13 companies have been established in this domain. Further, around 44% of the industry stakeholders are small companies. In addition, majority (47%) of the CD-47 therapeutics developers are based in North America, primarily in the US.

    Several clinical trials evaluating CD-47 targeting therapeutics have been registered worldwide
    Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 34.1%, during the period 2015-2020. Of the total, close to 13% of the studies have already been completed, followed by active trials that are actively recruiting patients (46.7%).

    Partnership activity within this domain has increased at a CAGR of 25.7%, between 2016 and 2020
    Clinical trial agreements emerged as the most popular type of partnership model adopted by industry stakeholders, followed by product development and commercialization agreements (25%), licensing agreements (25%), and services agreements (7.1%).

    USD 3.3+ billion has been invested by both private and public investors
    It is important to mention that, between 2016 and 2021, majority of the funding amount was raised through secondary offerings (46.5%), venture capital rounds (45%), IPO (15.6%) and debt financing (7.4%).

    North America is anticipated to capture over 85% of the market share, by 2035
    The market will be primarily driven by sales of CD-47 based therapeutics designed as biologics (over 60%), followed by those developed as small molecules (over 39%). Further, CD-47 based therapies targeting non-small cell lung cancer will capture the dominant share (23%) of the market (in terms of sales-based revenues); this trend is unlikely to change in the foreseen future.

    To request a sample copy / brochure of this report, please visit
    https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html

    Key Questions Answered

     Who are the leading players engaged in the development of CD47 targeting therapeutics?
     Which are the key drugs being developed across early and late stages of development?
     Which companies are actively involved in conducting clinical trials for their therapeutics?
     What is the evolving trend related to the focus of publications related to CD47 targeting therapeutics?
     What kind of partnership models are commonly adopted by industry stakeholders?
     Who are the key investors in this domain?
     Who are the key opinion leaders / experts in this field?
     What are the evolving social media trends related to CD47 targeting therapeutics?
     What are the different initiatives undertaken by big pharma players for the development of CD47 therapeutics in the recent past?
     How is the current and future opportunity likely to be distributed across key market segments?

    The financial opportunity within the CD-47 targeting therapeutics market has been analyzed across the following segments:
     Type of Molecule
     Biologics
     Small molecules

     Target Indications
     Acute Myeloid Leukemia
     Colorectal Neoplasms
     Diffuse-Large Cell Lymphoma
     Myelodysplastic Syndromes
     Non-Hodgkin Lymphoma
     Non-Small Cell Lung Cancer
     Oral Muscositis
     Ovarian Epithelial Cancer
     Small Cell Lung Cancer

     Key Players

     Key Geographical Regions
     US
     France
     Germany
     Italy
     Spain
     UK
     Australia
     China
     India
     Israel

    The research includes detailed profiles of 10+ developers by (listed below); the profiles also feature an overview of the developer, its financial information (if available), recent developments and an informed future outlook.

     Abpro
     ALX Oncology
     Apmonia Therapeutics
     Arch Oncology
     Aurigene
     Bristol Myers Squibb
     EpicentRx
     Forty Seven
     ImmuneOncia Therapeutics
     ImmuneOnco Biopharmaceuticals
     Innovent Biologics
     KAHR Medical
     Light Chain Bioscience
     Morphiex
     Trillium Therapeutics

    For additional details, please visit
    https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. RAS Targeting Therapies Market, 2021-2031
    2. Squamous NSCLC Market, 2021-2031
    3. Peptide Therapeutics Market, 2021-2031

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The CD-47 targeting therapeutics market is projected to grow at a CAGR of 42.9%, claims Roots Analysis Upon realizing the potential of this novel target, industry stakeholders have initiated several R&D efforts focused on exploiting the use of CD47 as an effective biomarker for the diagnosis and treatment purposes. Roots Analysis has announced the addition of “CD-47 Targeting Therapeutics Market, 2021-2035” report to its list of offerings. In recent years, the focus of the research community has shifted towards the development of novel treatment modalities, such as T- cell immunotherapies, that exhibit high efficacy. CD-47, owing to its increased expression on the surface of cancer cells, has emerged as a cancer immune checkpoint biomarker. To order this 190+ page report, which features 142+ figures, please visit https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html Key Market Insights Over 75 CD-47 drug candidates are under various phases of development 52% of the pipeline candidates are currently in preclinical and discovery stages, while more than 48% therapies are being evaluated in clinical stages with most candidates being in early clinical stages (41.6%); 3.9% and 2.6% of clinical candidates being evaluated in phase II and phase III respectively. ~50 companies claim to be engaged in the development of CD-47 therapeutics, globally Since 2015, 13 companies have been established in this domain. Further, around 44% of the industry stakeholders are small companies. In addition, majority (47%) of the CD-47 therapeutics developers are based in North America, primarily in the US. Several clinical trials evaluating CD-47 targeting therapeutics have been registered worldwide Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 34.1%, during the period 2015-2020. Of the total, close to 13% of the studies have already been completed, followed by active trials that are actively recruiting patients (46.7%). Partnership activity within this domain has increased at a CAGR of 25.7%, between 2016 and 2020 Clinical trial agreements emerged as the most popular type of partnership model adopted by industry stakeholders, followed by product development and commercialization agreements (25%), licensing agreements (25%), and services agreements (7.1%). USD 3.3+ billion has been invested by both private and public investors It is important to mention that, between 2016 and 2021, majority of the funding amount was raised through secondary offerings (46.5%), venture capital rounds (45%), IPO (15.6%) and debt financing (7.4%). North America is anticipated to capture over 85% of the market share, by 2035 The market will be primarily driven by sales of CD-47 based therapeutics designed as biologics (over 60%), followed by those developed as small molecules (over 39%). Further, CD-47 based therapies targeting non-small cell lung cancer will capture the dominant share (23%) of the market (in terms of sales-based revenues); this trend is unlikely to change in the foreseen future. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html Key Questions Answered  Who are the leading players engaged in the development of CD47 targeting therapeutics?  Which are the key drugs being developed across early and late stages of development?  Which companies are actively involved in conducting clinical trials for their therapeutics?  What is the evolving trend related to the focus of publications related to CD47 targeting therapeutics?  What kind of partnership models are commonly adopted by industry stakeholders?  Who are the key investors in this domain?  Who are the key opinion leaders / experts in this field?  What are the evolving social media trends related to CD47 targeting therapeutics?  What are the different initiatives undertaken by big pharma players for the development of CD47 therapeutics in the recent past?  How is the current and future opportunity likely to be distributed across key market segments? The financial opportunity within the CD-47 targeting therapeutics market has been analyzed across the following segments:  Type of Molecule  Biologics  Small molecules  Target Indications  Acute Myeloid Leukemia  Colorectal Neoplasms  Diffuse-Large Cell Lymphoma  Myelodysplastic Syndromes  Non-Hodgkin Lymphoma  Non-Small Cell Lung Cancer  Oral Muscositis  Ovarian Epithelial Cancer  Small Cell Lung Cancer  Key Players  Key Geographical Regions  US  France  Germany  Italy  Spain  UK  Australia  China  India  Israel The research includes detailed profiles of 10+ developers by (listed below); the profiles also feature an overview of the developer, its financial information (if available), recent developments and an informed future outlook.  Abpro  ALX Oncology  Apmonia Therapeutics  Arch Oncology  Aurigene  Bristol Myers Squibb  EpicentRx  Forty Seven  ImmuneOncia Therapeutics  ImmuneOnco Biopharmaceuticals  Innovent Biologics  KAHR Medical  Light Chain Bioscience  Morphiex  Trillium Therapeutics For additional details, please visit https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. RAS Targeting Therapies Market, 2021-2031 2. Squamous NSCLC Market, 2021-2031 3. Peptide Therapeutics Market, 2021-2031 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    CD-47 Targeting Therapeutics | Industry Analysis | Market Size | 2030
    CD-47 Targeting Therapeutics Market report features an extensive study of the current market...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The opportunity within the regulatory T-cell therapies market is projected to grow at an annualized rate of ~45%, till 2035, claims Roots Analysis

    Roots Analysis has done a detailed study on “Regulatory T-Cell Therapies Market, 2021 – 2035”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

    Given the various benefits offered, including high target specificity, customization potential and ability to generate immunological memory, regulatory T-cell (Treg) therapies have garnered significant attention among key industry stakeholders for the treatment of various oncological and non-oncological disease indications.

    To order this 145+ page report, which features 90+ figures and 60+ tables, please visit
    https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market.html

    Key Market Insights

     More than 150 industry players across the world are presently engaged in evaluating the potential of nearly 300 next generation immune checkpoint modulators for the treatment of multiple disease indications
     The pipeline features a variety of marketed / clinical stage therapies, targeting a number of different types of immune checkpoints and being investigated for administration via different routes
     In the last few years, over 600 clinical studies of various types of immune checkpoint modulation-based therapies, involving nearly 90,000 patients across different centers / hospitals, have been initiated worldwide
     In the pursuit of obtaining an edge within this emerging and highly competitive market landscape, developers are actively exploring the therapeutic potential of novel immune checkpoints, beyond PD-L1, PD-1 and CTLA-4
     Over time, big pharma players have initiated product development programs focused on immune checkpoint modulation for treating various oncological indications, investing significant capital, time and effort
     Several organizations have extended financial support to aid research efforts in this domain; the current focus is on investigation of novel immune checkpoint pathways / targets
     The growing interest in this field is also reflected by the 120+ partnerships have been signed in the last two years, involving both international and indigenous stakeholders
     The future market, based on the revenue generation potential of marketed and late stage therapies, is anticipated to be distributed across different disease areas, mechanisms and key geographical regions
     In the long term, the opportunity is likely to be segmented across diverse therapeutic modalities, immune checkpoint targets and routes of administration

    One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities associated with Treg cell therapies, over the coming decade. The report also includes likely sales forecasts of Treg cell therapies that are in the mid to late stages of development.

    To request a sample copy / brochure of this report, please visit this
    https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market/request-sample.html

    Table of Contents

    1. Preface

    2. Executive Summary

    3. Introduction

    4. Current Market Landscape

    5. Therapy Profiles

    6. Clinical Trial Analysis

    7. Partnerships and Collaborations

    8. Funding and Investment Analysis

    9. Porter’s Five Analysis

    10. Company Profiles

    11. Market Sizing and Opportunity Analysis

    12. Conclusion

    13. Executive Insights

    14. Appendices


    For more information, please visit https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market.html
    You may also be interested in the following reports :
    1. CD47 Targeting Therapeutics Market: Industry Trends and Global Forecasts, 2021-2030
    2. Antibody Drug Conjugates Market (6th Edition): Industry Trends and Global Forecasts, 2021-2030
    3. Novel T-Cell Immunotherapies Market: Industry Trends and Global Forecasts, 2021-2030
    4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030



    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The opportunity within the regulatory T-cell therapies market is projected to grow at an annualized rate of ~45%, till 2035, claims Roots Analysis Roots Analysis has done a detailed study on “Regulatory T-Cell Therapies Market, 2021 – 2035”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Given the various benefits offered, including high target specificity, customization potential and ability to generate immunological memory, regulatory T-cell (Treg) therapies have garnered significant attention among key industry stakeholders for the treatment of various oncological and non-oncological disease indications. To order this 145+ page report, which features 90+ figures and 60+ tables, please visit https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market.html Key Market Insights  More than 150 industry players across the world are presently engaged in evaluating the potential of nearly 300 next generation immune checkpoint modulators for the treatment of multiple disease indications  The pipeline features a variety of marketed / clinical stage therapies, targeting a number of different types of immune checkpoints and being investigated for administration via different routes  In the last few years, over 600 clinical studies of various types of immune checkpoint modulation-based therapies, involving nearly 90,000 patients across different centers / hospitals, have been initiated worldwide  In the pursuit of obtaining an edge within this emerging and highly competitive market landscape, developers are actively exploring the therapeutic potential of novel immune checkpoints, beyond PD-L1, PD-1 and CTLA-4  Over time, big pharma players have initiated product development programs focused on immune checkpoint modulation for treating various oncological indications, investing significant capital, time and effort  Several organizations have extended financial support to aid research efforts in this domain; the current focus is on investigation of novel immune checkpoint pathways / targets  The growing interest in this field is also reflected by the 120+ partnerships have been signed in the last two years, involving both international and indigenous stakeholders  The future market, based on the revenue generation potential of marketed and late stage therapies, is anticipated to be distributed across different disease areas, mechanisms and key geographical regions  In the long term, the opportunity is likely to be segmented across diverse therapeutic modalities, immune checkpoint targets and routes of administration One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities associated with Treg cell therapies, over the coming decade. The report also includes likely sales forecasts of Treg cell therapies that are in the mid to late stages of development. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market/request-sample.html Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Current Market Landscape 5. Therapy Profiles 6. Clinical Trial Analysis 7. Partnerships and Collaborations 8. Funding and Investment Analysis 9. Porter’s Five Analysis 10. Company Profiles 11. Market Sizing and Opportunity Analysis 12. Conclusion 13. Executive Insights 14. Appendices For more information, please visit https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market.html You may also be interested in the following reports : 1. CD47 Targeting Therapeutics Market: Industry Trends and Global Forecasts, 2021-2030 2. Antibody Drug Conjugates Market (6th Edition): Industry Trends and Global Forecasts, 2021-2030 3. Novel T-Cell Immunotherapies Market: Industry Trends and Global Forecasts, 2021-2030 4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Regulatory T-Cell Therapies Market | Market Size | Industry Analysis | 2035
    Regulatory T-Cell Therapies Market report features an extensive study of the current market landscape and future potential of the...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • TOP SELLING BIOLOGICS MARKET - CURRENT MARKET LANDSCAPE

    The “Top Selling Biologics Market, report features an extensive study of the current market landscape and future potential of the top selling biologics available for the treatment of a variety of disease indications.

    As of today, most of the top revenue generating drugs, across the globe, are biologics. During our research, we were able to identify 67 top selling biologics (revenues equal to or above USD 500 million in 2020). Top selling biologics market has so far been primarily led by industry players. Majority of industry players have taken a step towards investing their time and resources for the development of biologic therapies. Genentech, Amgen, Janssen Biotech, Sanofi and Novo Nordisk are amongst the major players in this domain. Biogen, AstraZeneca, Merck, Bristol Myers Squibb, GlaxoSmithKline, Alexion Pharmaceuticals, AbbVie and Novartis are other players that have entered the Top Selling Biologics domain in the past.

    To request a sample report: https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-sample.html

    It is worth highlighting that most of the therapies are monoclonal antibodies capture the highest share (54%) of the top selling biologics market. This can be attributed to the various advantages offered by them, including high reproducibility and specificity. It is also worth mentioning that these therapeutic modalities are being used for many cancer indications. Further, most of the top selling biologics are currently delivered via subcutaneous route of administration. However, most of the top selling biologics are available in the form of vials. This can be attributed to the better sterility assurance and reduced particle presence offered by such packaging formats.

    To order customize report: https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-customization.html

    It is worth highlighting that most of the therapies are being developed against autoimmune and oncological disorders; Oncological indications targeted by biologics include colorectal cancer (6), Non-Small Cell Lung Cancer (3), Breast Cancer (3), Hepatocellular Carcinoma (3), bladder cancer (3), urothelial carcinoma (3), and melanoma (3).

    For more information, please click on the following link:
    https://www.rootsanalysis.com/reports/top-selling-biologics-market.html

    You may also be interested in the following reports:
    1. Antibody Drug Conjugates Market
    2. Cell and Gene Therapy CROs Market
    3. Bispecific Antibody Therapeutics Market
    4. Genome Editing Services Market


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    TOP SELLING BIOLOGICS MARKET - CURRENT MARKET LANDSCAPE The “Top Selling Biologics Market, report features an extensive study of the current market landscape and future potential of the top selling biologics available for the treatment of a variety of disease indications. As of today, most of the top revenue generating drugs, across the globe, are biologics. During our research, we were able to identify 67 top selling biologics (revenues equal to or above USD 500 million in 2020). Top selling biologics market has so far been primarily led by industry players. Majority of industry players have taken a step towards investing their time and resources for the development of biologic therapies. Genentech, Amgen, Janssen Biotech, Sanofi and Novo Nordisk are amongst the major players in this domain. Biogen, AstraZeneca, Merck, Bristol Myers Squibb, GlaxoSmithKline, Alexion Pharmaceuticals, AbbVie and Novartis are other players that have entered the Top Selling Biologics domain in the past. To request a sample report: https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-sample.html It is worth highlighting that most of the therapies are monoclonal antibodies capture the highest share (54%) of the top selling biologics market. This can be attributed to the various advantages offered by them, including high reproducibility and specificity. It is also worth mentioning that these therapeutic modalities are being used for many cancer indications. Further, most of the top selling biologics are currently delivered via subcutaneous route of administration. However, most of the top selling biologics are available in the form of vials. This can be attributed to the better sterility assurance and reduced particle presence offered by such packaging formats. To order customize report: https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-customization.html It is worth highlighting that most of the therapies are being developed against autoimmune and oncological disorders; Oncological indications targeted by biologics include colorectal cancer (6), Non-Small Cell Lung Cancer (3), Breast Cancer (3), Hepatocellular Carcinoma (3), bladder cancer (3), urothelial carcinoma (3), and melanoma (3). For more information, please click on the following link: https://www.rootsanalysis.com/reports/top-selling-biologics-market.html You may also be interested in the following reports: 1. Antibody Drug Conjugates Market 2. Cell and Gene Therapy CROs Market 3. Bispecific Antibody Therapeutics Market 4. Genome Editing Services Market About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Top Selling Biologics Market 2021-2030 | Industry Analysis | Market Size | 2030
    Top Selling Biologics Market report features an extensive study of the current market landscape and future potential of the...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • Top Selling Biologics Market - Current Market Landscape

    The “Top Selling Biologics Market, report features an extensive study of the current market landscape and future potential of the top selling biologics available for the treatment of a variety of disease indications.

    As of today, most of the top revenue generating drugs, across the globe, are biologics. During our research, we were able to identify 67 top selling biologics (revenues equal to or above USD 500 million in 2020). Top selling biologics market has so far been primarily led by industry players. Majority of industry players have taken a step towards investing their time and resources for the development of biologic therapies. Genentech, Amgen, Janssen Biotech, Sanofi and Novo Nordisk are amongst the major players in this domain. Biogen, AstraZeneca, Merck, Bristol Myers Squibb, GlaxoSmithKline, Alexion Pharmaceuticals, AbbVie and Novartis are other players that have entered the Top Selling Biologics domain in the past.

    To request a sample report: https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-sample.html

    It is worth highlighting that most of the therapies are monoclonal antibodies capture the highest share (54%) of the top selling biologics market. This can be attributed to the various advantages offered by them, including high reproducibility and specificity. It is also worth mentioning that these therapeutic modalities are being used for many cancer indications. Further, most of the top selling biologics are currently delivered via subcutaneous route of administration. However, most of the top selling biologics are available in the form of vials. This can be attributed to the better sterility assurance and reduced particle presence offered by such packaging formats.

    To order customize report: https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-customization.html

    It is worth highlighting that most of the therapies are being developed against autoimmune and oncological disorders; Oncological indications targeted by biologics include colorectal cancer (6), Non-Small Cell Lung Cancer (3), Breast Cancer (3), Hepatocellular Carcinoma (3), bladder cancer (3), urothelial carcinoma (3), and melanoma (3).

    For more information, please click on the following link:
    https://www.rootsanalysis.com/reports/top-selling-biologics-market.html

    You may also be interested in the following reports:
    1. Antibody Drug Conjugates Market
    2. Cell and Gene Therapy CROs Market
    3. Bispecific Antibody Therapeutics Market
    4. Genome Editing Services Market


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    Top Selling Biologics Market - Current Market Landscape The “Top Selling Biologics Market, report features an extensive study of the current market landscape and future potential of the top selling biologics available for the treatment of a variety of disease indications. As of today, most of the top revenue generating drugs, across the globe, are biologics. During our research, we were able to identify 67 top selling biologics (revenues equal to or above USD 500 million in 2020). Top selling biologics market has so far been primarily led by industry players. Majority of industry players have taken a step towards investing their time and resources for the development of biologic therapies. Genentech, Amgen, Janssen Biotech, Sanofi and Novo Nordisk are amongst the major players in this domain. Biogen, AstraZeneca, Merck, Bristol Myers Squibb, GlaxoSmithKline, Alexion Pharmaceuticals, AbbVie and Novartis are other players that have entered the Top Selling Biologics domain in the past. To request a sample report: https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-sample.html It is worth highlighting that most of the therapies are monoclonal antibodies capture the highest share (54%) of the top selling biologics market. This can be attributed to the various advantages offered by them, including high reproducibility and specificity. It is also worth mentioning that these therapeutic modalities are being used for many cancer indications. Further, most of the top selling biologics are currently delivered via subcutaneous route of administration. However, most of the top selling biologics are available in the form of vials. This can be attributed to the better sterility assurance and reduced particle presence offered by such packaging formats. To order customize report: https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-customization.html It is worth highlighting that most of the therapies are being developed against autoimmune and oncological disorders; Oncological indications targeted by biologics include colorectal cancer (6), Non-Small Cell Lung Cancer (3), Breast Cancer (3), Hepatocellular Carcinoma (3), bladder cancer (3), urothelial carcinoma (3), and melanoma (3). For more information, please click on the following link: https://www.rootsanalysis.com/reports/top-selling-biologics-market.html You may also be interested in the following reports: 1. Antibody Drug Conjugates Market 2. Cell and Gene Therapy CROs Market 3. Bispecific Antibody Therapeutics Market 4. Genome Editing Services Market About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Top Selling Biologics Market 2021-2030 | Industry Analysis | Market Size | 2030
    Top Selling Biologics Market report features an extensive study of the current market landscape and future potential of the...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The RNA targeting small molecule therapies market

    In the recent years, RNA’s potential as a target molecule for small molecules has been widely recognized; as a result, a number of industry players have developed their proprietary technologies for direct and indirect RNA targeting and are actively engaged in the discovery and development of therapies against a wide range of therapeutic disorder

    Roots Analysis has announced the addition of “RNA Targeting Small Molecules Therapeutics Market, 2021-2030” report to its list of offerings.

    RNAs represent a one-of-a-kind class of molecules that can interact with three different types of biological macromolecules, namely DNA, RNA and proteins which further enables the development of therapies capable of targeting previously deemed undruggable transcripts and genes. In the past few years, a number of novel techniques have been developed to expand the druggability of RNA molecules. As a result, numerous small molecules, capable of acting on current and novel RNA targets are also being investigated in clinical and preclinical studies for the treatment of various indications, such as genetic diseases, infectious diseases and different types of cancers.

    To order this 260+ page report, which features 110+ figures, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html.

    Key Market Insights

    100+ RNA targeting small molecule therapeutics have been / are being developed for the treatment of different types of disease indications
    Close to 70% of the aforementioned therapeutic candidates are under preclinical evaluation. Further, two therapies, namely Translarna™ and Risdiplam, have been approved for the treatment of Duchenne Muscular Dystrophy and spinal muscular atrophy respectively.

    More than 45% of the therapies under clinical evaluation are currently in phase II developmental stage
    Around 50% of therapies under clinical evaluation are being developed to target oncological disorders; of which 53% of candidates are being evaluated under phase I clinical stage of development

    Close to 60% of the therapies under preclinical evaluation are currently in discovery phase of development
    Around 44% of the therapies under preclinical evaluation are being developed to target neurological disorders; of which close to 50% of drug candidates underwent RNA splicing modification.

    More than 55% of the players evaluating RNA Targeting small molecule therapies are small companies
    North America has emerged as a key hub, featuring the presence of 63% developers. The developer landscape is further dominated by players that have been established post-2012, representing around 68% of the total number of stakeholders

    Partnership activity in this field has increased at a CAGR of 9.1%, between 2018 and 2020
    More than 70% of the reported deals were R&D agreements, majority of which were focused on drug candidates targeting neurological disorders. Further, majority of the instances captured in the report were inked with players based in North America (65%).

    Close to USD 500 million was raised by companies involved in the development of drug candidates targeting oncological disorders
    Majority of the companies (52%) engaged in this domain primarily received funding through venture capital rounds. Further, around 90% of the funding instances were reported by players headquartered in the US.

    North America is anticipated to capture over ~70% of the global market share in 2030
    In 2030, close to 40% of the market revenues are expected to be generated from sales of therapeutics that are intended to target oncological disorders. Further, therapies designed for oral route of administration are expected to occupy a larger share (77%) of the overall market in 2030.

    To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market/request-sample.html

    Key Questions Answered
     Who are the key players engaged in the development of RNA targeting small molecule therapeutics?
     What are the current investment trends in this field?
     Which are the key therapeutic areas for which RNA targeting small molecule therapies are being developed?
     What are the different technological approaches adopted by various players for the development of RNA targeting small molecule therapeutics?
     What type of partnership models are most commonly adopted by stakeholders engaged in this domain?
     What is the relative competitiveness of different RNA targeting small molecule therapeutics developers engaged in this market?
     How is the current and future market opportunity likely to be distributed across key market segments?

    The USD XX million (by 2030) financial opportunity within the RNA targeting small molecules therapeutics market has been analyzed across the following segments:

     Drug
     Translarna™
     Risdiplam
     Tomivosertib
     ELX-02
     H3B-6545
     ABX464

     Type of Indication
     Aniridia
     Breast Cancer
     Castrate-resistant Prostate Cancer
     Colorectal Cancer
     Crohn Disease
     Cystic Fibrosis
     Duchenne Muscular Dystrophy
     Dravet Syndrome
     HIV Infections
     Impaired Renal Function
     NSCLC
     Rheumatoid Arthritis
     Spinal Muscular Atrophy
     Ulcerative Colitis

     Type of Therapeutic Area
     Autoimmune Disorders
     Genetic Disorders
     Inflammatory Disorders
     Infectious Disorders
     Kidney Disorders
     Neurological Disorders
     Oncological Disorders
     Ophthalmic Disorders
     Rare Disorders
     Respiratory Disorders

     Type of Target Molecule
     CDKL5
     Cap Binding Complex
     Dystrophin Protein
     Estrogen Receptor Alpha
     G542X
     MNK1 / MNK2 PAX6 Gene
     PAX6 Gene
     SMN2

     Type of Route of Administration
     Oral
     Subcutaneous

     Key Geographical Regions
     North America
     Europe

    The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.

     Abivax
     AC immune
     Arrakis Therapeutics
     eFFECTOR Therapeutics
     Eloxx Pharmaceuticals
     H3 Biomedicine
     PTC Therapeutics
     Ribometrix
     Skyhawk Therapeutics
     STORM Therapeutics


    For additional details, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. RAS Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    2. DNA Damage Response Targeting Therapeutics: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    3. HER2 Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The RNA targeting small molecule therapies market In the recent years, RNA’s potential as a target molecule for small molecules has been widely recognized; as a result, a number of industry players have developed their proprietary technologies for direct and indirect RNA targeting and are actively engaged in the discovery and development of therapies against a wide range of therapeutic disorder Roots Analysis has announced the addition of “RNA Targeting Small Molecules Therapeutics Market, 2021-2030” report to its list of offerings. RNAs represent a one-of-a-kind class of molecules that can interact with three different types of biological macromolecules, namely DNA, RNA and proteins which further enables the development of therapies capable of targeting previously deemed undruggable transcripts and genes. In the past few years, a number of novel techniques have been developed to expand the druggability of RNA molecules. As a result, numerous small molecules, capable of acting on current and novel RNA targets are also being investigated in clinical and preclinical studies for the treatment of various indications, such as genetic diseases, infectious diseases and different types of cancers. To order this 260+ page report, which features 110+ figures, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html. Key Market Insights 100+ RNA targeting small molecule therapeutics have been / are being developed for the treatment of different types of disease indications Close to 70% of the aforementioned therapeutic candidates are under preclinical evaluation. Further, two therapies, namely Translarna™ and Risdiplam, have been approved for the treatment of Duchenne Muscular Dystrophy and spinal muscular atrophy respectively. More than 45% of the therapies under clinical evaluation are currently in phase II developmental stage Around 50% of therapies under clinical evaluation are being developed to target oncological disorders; of which 53% of candidates are being evaluated under phase I clinical stage of development Close to 60% of the therapies under preclinical evaluation are currently in discovery phase of development Around 44% of the therapies under preclinical evaluation are being developed to target neurological disorders; of which close to 50% of drug candidates underwent RNA splicing modification. More than 55% of the players evaluating RNA Targeting small molecule therapies are small companies North America has emerged as a key hub, featuring the presence of 63% developers. The developer landscape is further dominated by players that have been established post-2012, representing around 68% of the total number of stakeholders Partnership activity in this field has increased at a CAGR of 9.1%, between 2018 and 2020 More than 70% of the reported deals were R&D agreements, majority of which were focused on drug candidates targeting neurological disorders. Further, majority of the instances captured in the report were inked with players based in North America (65%). Close to USD 500 million was raised by companies involved in the development of drug candidates targeting oncological disorders Majority of the companies (52%) engaged in this domain primarily received funding through venture capital rounds. Further, around 90% of the funding instances were reported by players headquartered in the US. North America is anticipated to capture over ~70% of the global market share in 2030 In 2030, close to 40% of the market revenues are expected to be generated from sales of therapeutics that are intended to target oncological disorders. Further, therapies designed for oral route of administration are expected to occupy a larger share (77%) of the overall market in 2030. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market/request-sample.html Key Questions Answered  Who are the key players engaged in the development of RNA targeting small molecule therapeutics?  What are the current investment trends in this field?  Which are the key therapeutic areas for which RNA targeting small molecule therapies are being developed?  What are the different technological approaches adopted by various players for the development of RNA targeting small molecule therapeutics?  What type of partnership models are most commonly adopted by stakeholders engaged in this domain?  What is the relative competitiveness of different RNA targeting small molecule therapeutics developers engaged in this market?  How is the current and future market opportunity likely to be distributed across key market segments? The USD XX million (by 2030) financial opportunity within the RNA targeting small molecules therapeutics market has been analyzed across the following segments:  Drug  Translarna™  Risdiplam  Tomivosertib  ELX-02  H3B-6545  ABX464  Type of Indication  Aniridia  Breast Cancer  Castrate-resistant Prostate Cancer  Colorectal Cancer  Crohn Disease  Cystic Fibrosis  Duchenne Muscular Dystrophy  Dravet Syndrome  HIV Infections  Impaired Renal Function  NSCLC  Rheumatoid Arthritis  Spinal Muscular Atrophy  Ulcerative Colitis  Type of Therapeutic Area  Autoimmune Disorders  Genetic Disorders  Inflammatory Disorders  Infectious Disorders  Kidney Disorders  Neurological Disorders  Oncological Disorders  Ophthalmic Disorders  Rare Disorders  Respiratory Disorders  Type of Target Molecule  CDKL5  Cap Binding Complex  Dystrophin Protein  Estrogen Receptor Alpha  G542X  MNK1 / MNK2 PAX6 Gene  PAX6 Gene  SMN2  Type of Route of Administration  Oral  Subcutaneous  Key Geographical Regions  North America  Europe The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.  Abivax  AC immune  Arrakis Therapeutics  eFFECTOR Therapeutics  Eloxx Pharmaceuticals  H3 Biomedicine  PTC Therapeutics  Ribometrix  Skyhawk Therapeutics  STORM Therapeutics For additional details, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. RAS Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 2. DNA Damage Response Targeting Therapeutics: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 3. HER2 Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    0 Comments 0 Shares

No results to show

No results to show

No results to show

No results to show

Sponsored